GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiGen Biopharmaceuticals Holdings Ltd (ROCO:4157) » Definitions » Research & Development

TaiGen Biopharmaceuticals Holdings (ROCO:4157) Research & Development : NT$154.7 Mil (TTM As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is TaiGen Biopharmaceuticals Holdings Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. TaiGen Biopharmaceuticals Holdings's Research & Development for the three months ended in Mar. 2025 was NT$28.8 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was NT$154.7 Mil.


TaiGen Biopharmaceuticals Holdings Research & Development Historical Data

The historical data trend for TaiGen Biopharmaceuticals Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiGen Biopharmaceuticals Holdings Research & Development Chart

TaiGen Biopharmaceuticals Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 249.44 283.28 237.52 187.48 166.07

TaiGen Biopharmaceuticals Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.17 40.92 42.55 42.43 28.81

TaiGen Biopharmaceuticals Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$154.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TaiGen Biopharmaceuticals Holdings  (ROCO:4157) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


TaiGen Biopharmaceuticals Holdings Research & Development Related Terms

Thank you for viewing the detailed overview of TaiGen Biopharmaceuticals Holdings's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


TaiGen Biopharmaceuticals Holdings Business Description

Traded in Other Exchanges
N/A
Address
No. 138 Xinming Road, 7th Floor, Neihu District, Taipei, TWN, 114
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other.

TaiGen Biopharmaceuticals Holdings Headlines

No Headlines